Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms

Key facts

Sponsor

Imperial College London

Intervention

Exhaled breath sampling(other)

Enrollment

518 target

Eligibility

18-90 years · All sexes

Timeline

2023 – 2026

Study locations (13)

• Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom
• Hull University Teaching Hospitals NHS Trust, Cottingham, Hull, United Kingdom
• Cardiff and Vale University Health Board, Cardiff, United Kingdom
• Velindre NHS Trust, Cardiff, United Kingdom
• University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
• University Hospitals of Leicester NHS Foundation Trust, Leicester, United Kingdom
• Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
• The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom
• Bedfordshire Hospitals NHS Foundation Trust, Luton, United Kingdom
• Newcastle Upon Tyne Hospitals NHS Trust, Newcastle, United Kingdom
• Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
• Oxford University Hospitals NHS Trust, Oxford, United Kingdom
• Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom

Collaborators

Imperial College Healthcare NHS Trust · Hull University Teaching Hospitals NHS Trust · Norfolk and Norwich University Hospitals NHS Foundation Trust · University Hospitals Coventry and Warwickshire NHS Trust · Oxford University Hospitals NHS Trust · Velindre NHS Trust · Cardiff and Vale University Health Board · Newcastle-upon-Tyne Hospitals NHS Trust · Liverpool University Hospitals NHS Foundation Trust · Bedfordshire Hospitals NHS Foundation Trust · University Hospitals, Leicester · The Clatterbridge Cancer Centre NHS Foundation Trust · Portsmouth Hospitals NHS Trust · University Hospital Plymouth NHS Trust · NHS Tayside · NHS Highlands · The Christie NHS Foundation Trust · North Cumbria University Hospitals NHS Trust · Maidstone & Tunbridge Wells NHS Trust · University Hospitals of Derby and Burton NHS Foundation Trust · Bradford Teaching Hospitals NHS Foundation Trust · East and North Hertfordshire NHS Trust

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the esophagus

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07457528
  Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE2NCT07331155
  A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
  Nanjing Leads Biolabs Co.,Ltd
• RECRUITINGPHASE1NCT07503808
  A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  IDEAYA Biosciences
• RECRUITINGPHASE2NCT07403136
  Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT07385001
  A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
  Tang-Du Hospital
• RECRUITINGPHASE2NCT07263919
  Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
  Akeso
• RECRUITINGPHASE2NCT07481058
  KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
  Beijing Konruns Pharmaceutical Co., Ltd.
• RECRUITINGPHASE1NCT07217171
  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
  EvolveImmune United, Inc

See all trials for Squamous cell carcinoma of the esophagus →